Publicaciones en las que colabora con José Alberto Orfao de Matos Correia e Vale (17)

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2016

  1. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

    Blood, Vol. 127, Núm. 25, pp. 3165-3174

  2. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance

    Blood, Vol. 127, Núm. 15, pp. 1896-1906

2015

  1. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

  2. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

  2. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

    Haematologica, Vol. 98, Núm. 1, pp. 79-86

  3. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

    Blood, Vol. 122, Núm. 22, pp. 3591-3598

  4. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (Leukemia (2013) 27 (2112))

    Leukemia

2012

  1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

    Haematologica, Vol. 97, Núm. 7, pp. 1110-1114

2011

  1. Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.

    Clinical lymphoma, myeloma & leukemia, Vol. 11, Núm. 1, pp. 168-171

2005

  1. Cell cycle analysis of Waldenström's macroglobulinemia

    Clinical Lymphoma, Vol. 5, Núm. 4, pp. 250-252

  2. Immunophenotypic and cytogenetic comparison of Waldenström's macroglobulinemia with splenic marginal zone lymphoma

    Clinical Lymphoma, Vol. 5, Núm. 4, pp. 241-245

2003

  1. Immunophenotypic analysis of Waldenstrom's macroglobulinemia

    Seminars in Oncology, Vol. 30, Núm. 2, pp. 187-195

2002

  1. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival

    British Journal of Haematology, Vol. 118, Núm. 4, pp. 1034-1040